Skip to main content
All targets are shown
Gene
Drug Category
Drug Class
Download CSV
Gene NCT ID Antigen/Ligand Binding Type Drug Name Drug Type Drug NCI Concept Drug Category Drug Class Drug Description Drug Mechanism of Action Cytotoxicity Cytotoxicity Type Target Cytotoxicity Mechanism Disease Disease Type Tissue OncoTree Main Type OncoTree Name Annotation Status
EGFR NCT05299125 EGFR antigen recognition Amivantamab RELEVANT_DRUG C124993 INHIBITORY ANTIBODY Inhibitor Low-fucose, fully human IgG1 bispecific monoclonal antibody targeting EGFR and MET; inhibits EGFR/MET signaling and active against EGFR activating/resistance mutations (e.g., T790M/C797S) and MET pathway activation. Low-fucose, fully human IgG1 bispecific antibody that targets EGFR and MET (wild-type and mutant), blocks ligand binding and receptor phosphorylation, promotes receptor internalization/degradation, and mediates Fc-dependent ADCC; collectively shuts down EGFR/MET downstream signaling (e.g., MAPK, PI3K-AKT) and inhibits tumor cell proliferation, including in EGFR-activating/resistance and MET-driven settings. YES DIRECT Amivantamab binds EGFR on target cells and engages Fcγ receptors on immune effectors to trigger ADCC (and ADCP), killing EGFR-positive cells; it also induces receptor internalization/degradation and signaling blockade (mainly cytostatic). Metastatic Non-Small Cell Lung Cancer CANCER Lung Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer ai
MET NCT05299125 MET (c-MET/HGFR) antigen recognition Amivantamab RELEVANT_DRUG C124993 INHIBITORY ANTIBODY Inhibitor Low-fucose, fully human IgG1 bispecific monoclonal antibody targeting EGFR and MET; inhibits EGFR/MET signaling and active against EGFR activating/resistance mutations (e.g., T790M/C797S) and MET pathway activation. Low-fucose, fully human IgG1 bispecific antibody that targets EGFR and MET (wild-type and mutant), blocks ligand binding and receptor phosphorylation, promotes receptor internalization/degradation, and mediates Fc-dependent ADCC; collectively shuts down EGFR/MET downstream signaling (e.g., MAPK, PI3K-AKT) and inhibits tumor cell proliferation, including in EGFR-activating/resistance and MET-driven settings. YES DIRECT Amivantamab binds MET on target cells and engages Fcγ receptor–bearing effector cells to mediate Fc-dependent ADCC (and phagocytosis), leading to target-cell killing; it also induces receptor internalization/degradation and signaling blockade. Metastatic Non-Small Cell Lung Cancer CANCER Lung Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer ai
EGFR NCT05299125 EGFR exon 19 deletion mutant (Del19) other Lazertinib RELEVANT_DRUG C148147 SMALL MOLECULE DRUG Inhibitor Mutant-selective small-molecule EGFR tyrosine kinase inhibitor active against Ex19del/L858R and T790M with reduced activity on wild-type EGFR. Third-generation, mutant-selective EGFR tyrosine kinase inhibitor that irreversibly binds mutant EGFR (e.g., Ex19del, L858R, T790M), blocking EGFR signaling with minimal activity on wild-type EGFR, leading to tumor cell death; penetrates the blood-brain barrier. YES DIRECT Mutant-selective EGFR TKI that irreversibly inhibits EGFR Del19 kinase activity, blocking downstream survival signaling (e.g., PI3K/AKT, MAPK) and inducing apoptosis of EGFR-mutant tumor cells. Metastatic Non-Small Cell Lung Cancer CANCER Lung Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer ai
EGFR NCT05299125 EGFR L858R mutant other Lazertinib RELEVANT_DRUG C148147 SMALL MOLECULE DRUG Inhibitor Mutant-selective small-molecule EGFR tyrosine kinase inhibitor active against Ex19del/L858R and T790M with reduced activity on wild-type EGFR. Third-generation, mutant-selective EGFR tyrosine kinase inhibitor that irreversibly binds mutant EGFR (e.g., Ex19del, L858R, T790M), blocking EGFR signaling with minimal activity on wild-type EGFR, leading to tumor cell death; penetrates the blood-brain barrier. YES DIRECT Mutant-selective, irreversible inhibition of EGFR L858R blocks EGFR signaling (e.g., MAPK/PI3K), triggering apoptosis of EGFR-mutant tumor cells. Metastatic Non-Small Cell Lung Cancer CANCER Lung Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer ai
EGFR NCT05299125 EGFR T790M resistance mutant other Lazertinib RELEVANT_DRUG C148147 SMALL MOLECULE DRUG Inhibitor Mutant-selective small-molecule EGFR tyrosine kinase inhibitor active against Ex19del/L858R and T790M with reduced activity on wild-type EGFR. Third-generation, mutant-selective EGFR tyrosine kinase inhibitor that irreversibly binds mutant EGFR (e.g., Ex19del, L858R, T790M), blocking EGFR signaling with minimal activity on wild-type EGFR, leading to tumor cell death; penetrates the blood-brain barrier. YES DIRECT Lazertinib irreversibly inhibits the EGFR T790M mutant kinase, blocking downstream survival signaling (e.g., PI3K/AKT, MAPK) and inducing apoptosis of EGFR-mutant tumor cells. Metastatic Non-Small Cell Lung Cancer CANCER Lung Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer ai
Displaying 1691 - 1695 of 5381